Cargando…
Non-anticoagulant heparin derivatives for COVID-19 treatment
The ongoing pandemic of COVID-19, caused by the infection of SARS-CoV-2, has generated significant harm to the world economy and taken numerous lives. This syndrome is characterized by an acute inflammatory response, mainly in the lungs and kidneys. Accumulated evidence suggests that exogenous hepar...
Autores principales: | Cao, Min, Qiao, Meng, Sohail, Muhammad, Zhang, Xing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749384/ https://www.ncbi.nlm.nih.gov/pubmed/36528145 http://dx.doi.org/10.1016/j.ijbiomac.2022.12.090 |
Ejemplares similares
-
Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023) -
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
por: Buijsers, Baranca, et al.
Publicado: (2020) -
Non-Anticoagulant Heparins Are Hepcidin Antagonists for the Treatment of Anemia
por: Poli, Maura, et al.
Publicado: (2017) -
Non-Anticoagulant Heparins as Heparanase Inhibitors
por: Cassinelli, Giuseppe, et al.
Publicado: (2020) -
The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19
por: Braz-de-Melo, Heloísa Antoniella, et al.
Publicado: (2021)